Groningen, the Netherlands - May 19, 2015 – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, announces that its Chief Scientific Officer, Dr. Kees Leenhouts, will present at the Modern Vaccines Adjuvants & Delivery Systems (MVADS) 2015 conference held today at the Leiden University Medical Center in The Netherlands. Dr. Leenhouts will present about the value of Mucosis’ unique and stable prefusion F antigen for use in vaccine delivery, as well as progress with the company’s intranasal respiratory syncytial virus (RSV) vaccine candidate, SynGEM®.
Dr. Leenhouts will discuss the significance of Mucosis’ prefusion F antigen construct, which elicits locally secreted Immunoglobulin A (IgA) in the mucosal layers and a balanced Th1/Th2-type of systemic immune response. This protects the body from disease causing pathogens right at their port of entry, the mucosal pathways, where over 90% of pathogens enter.
The prefusion F antigen is used in Mucosis’ lead product, SynGEM®, a vaccine against RSV, a disease which causes potentially fatal respiratory tract infections for which there is currently no treatment. The vaccine uses Mucosis’ proprietary vaccine delivery platform, Mimopath®, to provide needle-free administration via the nasal pathway. An update on the development progress of SynGEM®, currently nearing clinical program start, will also be presented at MVADS 2015.
This will be the 5th International MVADS conference (18-20 May), held annually to support the continual demand and development of new vaccines with effective delivery systems and adjuvants. Attendance at the event is anticipated to include a variety of different bodies in the vaccines space, including academic researchers as well as industrial, governmental and regulatory groups.
Dr. Kees Leenhouts, Chief Scientific Officer of Mucosis, commented,”MVADS 2015 is a great opportunity for Mucosis to share with the scientific community our advances in the vaccine delivery area for the critical unmet medical need in preventing RSV and other infections worldwide.”
Mucosis is to present ‘Development of the intranasal RSV vaccine SynGEM®’ today in session 5, ‘Mucosal/ Intranasal’.
About Mucosis www.mucosis.com
Mucosis B.V. (Mucosis) is a clinical-stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases. Mucosis’s investigational patient-friendly vaccines can be delivered via the nose or mouth to elicit a more natural immune response with a broader base of protection. The company is developing multiple programs for its clinical-stage proprietary Mimopath® platform vaccine technology for several routes of administration including those that provide additional mucosal protection, where over 90% of pathogens enter the human body.
Mucosis’s lead product SynGEM®, a stabilized recombinant vaccine delivered intranasally to prevent respiratory syncytial virus (RSV) infection, will enter human proof-of-concept studies in 2016. The annual global burden of RSV illness is significant, with 33.8 million estimated new episodes of RSV-associated acute lower respiratory infection (ALRI) worldwide in children under 5, and over 3.4 million hospital admissions associated with severe RSV disease. Global mortality was estimated at 253,500 deaths in 2010.
The company has also developed PneuGEM®, a vaccine to prevent diseases caused by pneumococcal bacteria, and FluGEM®, a vaccine against influenza. FluGEM® served as a successful proof of concept for the Mimopath® platform in human clinical testing.
Mucosis has raised over EUR 20m, with key investment partners including BCHT, MedSciences, BioGeneration, NOM & UU Holdings. The company has strategic partnerships in US, Asia and the EU with organizations including the US National Institutes of Health, China-based Changchun BCHT Biotechnology co., and the Netherlands Enterprise Agency. Mucosis’s management is highly experienced in the design, development and commercialization of vaccines. Mucosis employs over 10 staff at its headquarters in Groningen, The Netherlands.
Issued for and on behalf of Mucosis by Instinctif Partners.
For more information please contact: email@example.com
Sue CharlesManaging Partner